Beximco Pharmaceuticals (LON:BXP) Stock Price Up 15.4% - Should You Buy?

Key Points

• Beximco Pharmaceuticals stock surged by 15.4% during trading on Wednesday, reaching a last traded price of GBX 45 ($0.60).
• The stock's trading volume increased significantly, with 183,946 shares changing hands, a 252% rise compared to its average session volume.
• As of the latest report, Beximco Pharmaceuticals has a market capitalization of £30.30 billion and a P/E ratio of 4.77.

Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report)'s share price shot up 15.4% during mid-day trading on Wednesday . The company traded as high as GBX 45 ($0.61) and last traded at GBX 45 ($0.61). 183,946 shares traded hands during trading, an increase of 252% from the average session volume of 52,207 shares. The stock had previously closed at GBX 39 ($0.52).

Beximco Pharmaceuticals Price Performance

The stock has a market capitalization of £30.33 billion, a price-to-earnings ratio of 4.77 and a beta of 0.61. The company has a quick ratio of 0.37, a current ratio of 2.13 and a debt-to-equity ratio of 12.47. The business's 50 day simple moving average is GBX 38.64 and its 200-day simple moving average is GBX 38.05.

Beximco Pharmaceuticals Company Profile

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.